Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025

Candel Therapeutics (CADL) will present positive Phase 3 trial results for CAN-2409 in intermediate-to-high-risk localized prostate cancer at ASCO 2025, demonstrating a 30% reduction in cancer recurrence or death when added to standard radiotherapy. The trial, involving 745 patients, also showed a significant benefit in prostate cancer-free survival and a higher rate of pathological complete response (80.4% vs 63.6% in the placebo group) with CAN-2409, reinforcing the potential for improved local control of the disease.

Analysis

Candel Therapeutics (NASDAQ:CADL) is poised to present compelling Phase 3 trial data for its lead candidate, CAN-2409, in intermediate-to-high-risk localized prostate cancer at the prestigious 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3. The study, involving 745 patients, successfully met both primary and secondary endpoints, demonstrating that CAN-2409, when added to standard of care radiotherapy and valacyclovir, achieved a 30% reduction in the risk of cancer recurrence or death compared to placebo. Furthermore, the treatment showed a significant benefit in prostate cancer-free survival and an increased proportion of patients achieving a prostate-specific antigen (PSA) nadir below 0.2 ng/ml. A key finding from two-year post-treatment biopsies revealed an 80.4% pathological complete response rate in the CAN-2409 arm, substantially higher than the 63.6% observed in the control group, a result reinforced by tissue analysis suggesting potential microscopic cancer elimination. CAN-2409 was reported as generally well tolerated, with most common side effects being mild to moderate flu-like symptoms, indicating a favorable safety profile. This positive clinical outcome, underscored by a strongly positive sentiment score of 0.85 and a specific CADL sentiment of 0.9, alongside a market impact score of 0.75, suggests significant potential for CAN-2409 to improve local control and treatment paradigms for prostate cancer patients seeking curative intent.

Key Decisions for Investors

• The positive Phase 3 results for CAN-2409 represent a significant clinical de-risking event for Candel Therapeutics and could favorably impact its valuation, pending regulatory pathways and market reception.
• Investors should closely monitor the detailed data presentation at the ASCO Annual Meeting on June 3, 2025, and subsequent peer reviews, as this will likely be a key near-term catalyst for CADL's stock.
• Given the robust efficacy metrics, including a 30% reduction in recurrence/death and an 80.4% pathological complete response rate, alongside a favorable safety profile, further due diligence on the market potential and Candel's commercialization strategy for CAN-2409 is warranted.